Dechert Advises DNA Script on US$38.5 million Series B Fundraising
May 17, 2019
PARIS - Dechert LLP advised DNA Script, the world's leading company in manufacturing de novo synthetic nucleic acids using an enzymatic technology, in connection with its Series B fundraising of $38.5 million.
The fundraising was led by LSP, one of Europe's largest healthcare investment firms, and also involved French national investment bank Bpifrance, through its Large Venture fund, alongside existing investors Illumina Ventures, M. Ventures, Sofinnova Partners, Kurma Partners and Idinvest Partners.
The proceeds will allow DNA Script to accelerate the development of the company's first products based on its enzymatic technology for de novo synthesis of nucleic acids. The company is focusing on recruitment of top talent in the U.S. for its product development and commercialization teams in preparation for product launch, as well as on expanding its Paris-based research team.
The Dechert Paris-based team advising DNA Script on the legal aspects included corporate partner Anne-Charlotte Rivière with corporate associate Claire Tanguy, IP partner Marie Fillon and Labor partner Philippe Thomas with Labor associate Thibault Meiers.
About Dechert
Dechert is a leading global law firm with 26 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.
Related Professionals
